05:32 PM EDT, 03/27/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) started dosing the first patient in the fourth cohort of its phase 1 cancer treatment trial.

Two more patients in the cohort are set to receive the TTX-MC138 "to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer," the company said Thursday in a statement.

"No significant safety or dose limiting toxicities have been reported," and additional patients are being evaluated for expanded enrollment, the company said.

Shares of the company rose 28% in after-hours trading.

Price: 0.6650, Change: +0.15, Percent Change: +27.88